It has been shown that cancer patients may develop a cellmediated and humoral response to various associated antigens. This recognition process is difficult to identify because the responses expressed by both patients and healthy individuals are not specific. The target structures for immune recognition that have been characterized do not show real tumour specificity in most experiments, but the presence of antibodies during malignancies may be clinically important for prognosis and follow up (Mastrangelo et al., 1984) . In contrast to recent progress in the cellular immunology of cancer, the role of humoral immunity in oncogenesis remains poorly understood.
'Serum enhancement' and 'blocking antibody' theories suggest that B cell activation and antibody production could promote tumour growth (Smith & Landy, 1970) . On the other hand, numerous studies deal with the fact that specific antibodies can inhibit tumour cell growth in vitro or in vivo. It has been shown that the level of circulating antitumour antibodies may be modulated by tumour treatment. The fact that antibodies may be effective in preventing the development of metastasis rather than blocking the growth of the primary tumour has also stressed the positive aspects of humoral antitumour immunity (Seto et al., 1983; Witz, 1977; Vaage & Agarwal, 1974) . Chemically induced tumours are often immunogenic: the host responds specifically in vivo to the tumour by generating a state of concomitant antitumour immunity (North, 1985) .
Among spontaneously occurring human tumours, the specific immune recognition of antigenic tumour cells may be restricted to virally induced tumour and in particular to those associated with DNA viruses (Klein & Klein, 1985) . Although several tumour antigens have been claimed to be specific, and analysed for their role in immunological responses in tumour-bearing host (Sulitzeanu, 1985) , the immunogenicity of cellular oncogene products has not yet been reported. Among the latter is the myc family of oncogenes, the expression of which has been demonstrated in many tumours and cancer cell lines (Slamon et al., 1984; Sikora et al., 1985) .
We have previously described the presence in the archaebacterium Halobacterium halobium genome of DNA fragments which hybridize with a v-myc probe. A comparison of appropriate H. halobium genomic clones with the v-myc gene showed regions of significant homology (Ben-Mahrez et al., 1988a) . Moreover, hybridization experiments showed that these bacteria possess two RNA molecules homologous to the v-myc oncogene (Ben-Mahrez et al., 1988b) .
Experiments on the immunogenicity of the myc oncogene product are restricted by the fact that the purified protein is not available in quantity. We report here a solution to the problem of protein limitation, using the properties of a protein from H. halobium which reacts with an anti-human c-myc antiserum. Preliminary experiments suggest that the myc oncogene product could be immunogenic during the transformation process and that it is possible to detect antibodies against the myc protein in the serum of some cancer patients.
Materials and methods
Strain and culture H. halobium CCM2090 was cultured in classical halophilic medium as described previously (Sehgal & Gibbons, 1960) to an absorbance of 1.4 at 600nm.
Eukaryotic cell cultures HL-60 cells were cultured as previously described (Grosso & Pitot, 1984) . MCF-7 and OD262 cells were cultured in 10% foetal calf serum in MEM medium, at 37°C in 5% CO2 (Kozbor & Croce, 1984 Research Center (Japan). The E peptide sequence is: HisGln-His-Asn-Tyr-Ala-Ala-Pro-Pro-Ser-Thr-Arg-Lys (amino acids 305 to 318 of the human c-myc protein). The F peptide corresponds to the carboxy-terminal amino acid sequence of the human c-myc protein (Colby et al., 1983) : Arg-Lys-ArgArg-Glu-Gln-Leu-Lys-His-Lys-Leu-Glu-Gln-Leu-Arg-AsnSer-Cys-Ala. Figure 1 demonstrates that a protein of 84kD present in fast sedimenting materials cross reacted with the anti-human cmyc antiserum. Such a cross-reacting protein was not seen in the soluble fraction.
We have examined whether this antiserum specifically recognizes the human c-myc protein. Using extracts of a human promyelocytic leukaemia cell line, HL-60, which is known to express c-myc (Grosso & Pitot, 1984) , it was found that the anti-human c-myc reacted with two proteins of 60 kD and 42 kD (Figure 2a) .
The presence of dimethylsulfoxide in HL-60 cell cultures is known to inhibit the synthesis of the c-myc protein (Grosso & Pitot, 1984) . The disappearance of both the 60 kD and 42 kD proteins was observed after 48 h dimethylsulfoxide treatment (Figure 2b ). It has already been reported that a 47 or 49 kD protein has a similar epitope to the c-myc protein and is subject to dimethylsulfoxide treatment (Faletto et al., 1985; Persson et al., 1984a) . As the c-myc product is a nuclear protein, but the 47 kD protein is not (Persson & Leder, 1984b) , HL-60 nuclei were purified, extracted and tested with the anti-human c-myc antiserum. Only a peptide of 60 kD was detected by Western blot analysis (Figure 3c) .
In order to confirm the identity between the 60 kD protein and the c-myc protein, two other human cell lines were examined, a breast carcinoma cell line MCF-7 which is negative (Kozbor & Croce, 1984) and an ovary carcinoma cell line OD262 which is positive, for c-myc expression. Figure 4 demonstrates that the 60 kD protein was detected both in HL-60 and OD262 but not in MCF-7. From these results it was concluded that the 60 kD protein recognized by the antiserum (Oncor Inc.) is the human c-myc gene product. Figure 5 . In order to confirm the validity of the test, Western blot analysis was carried out using extracts of dimethylsulfoxide treated or untreated HL-60 cells. Despite the complexity of bands due to the homologous system, a band of 60kD with a positive patient was seen only in extracts of non-differentiated HL-60 ( Figure 6) ; which indicated recognition of the c-myc protein by the positive serum. The c-myc protein being found in nuclei, it was determined whether the 60kD protein recognized by the positive serum was present in nuclear extracts. Figure 7 clearly shows that the positive serum reacted with a nuclear 60 kD protein. Competition between the 84kD protein and synthetic c-myc peptides
Further evidence that the positive sera contain antibodies against epitopes of the c-myc protein was obtained when positive sera were pre-incubated with either peptide E corresponding to the amino acid sequence of the c-myc protein (305-318) or the peptide F(421-439). Recognition of the 84kD protein by a positive serum was diminished after preincubation with either of the two synthetic peptides ( Figure  8A ). Interestingly, another positive serum reacted only with peptide F and not with peptide E (Figure 8B ).
These results demonstrate that the positive sera contain antibodies against epitopes contained in the amino acid sequences E and F of the c-myc protein. (fl, f2, f3) in buffer X, for 4 h at 40C and then tested by Western blot analysis using partially purified 84 kD protein as described in the legend of Figure 5 . The peptides were used at 50Ing ir (e1,f1); 50ngml (e2,f2) and lugmll (e3f3) Test without pre-incubation (1/20 dilution) (a, b).
Discussion
Archaebacteria possess several eukaryotic charactenistics (Zillig et al., 1985) . This observation has been supported by immunological techniques which have shown that the RNA polymerase or the alpha type DNA polymerase from archaebacteria share common epitopes with their eukaryotic counterparts (Huet et al., 1983; Kohiyama et al. 1986 ). In the same way we have identified an 84 kD protein from H. halobium having similar epitopes to the human c-myc protein and developed a serological screening test to detect antibodies against the c-myc product.
The human c-myc protein was identified in the present paper as a nuclear protein from HL 60 cells of approximately 60 kD by Western blot analysis using a commercial anti-human c-myc antiserum. However, in common with other authors (Faletto et al. 1985; Persson et al.1984a) this antiserum was found to recognize not only the c-myc protein but also another peptide of 42kD. The latter protein disappears more slowly than the c-myc gene product when HL-60 cells are treated with dimethylsulfoxide (Faletto et al., 1985) . In the absence of absolute specificity of the antiserum the question was raised whether the 84kD protein recognized by the c-myc antiserum was similar to the human 42kD protein rather than to the human c-myc product. To answer the question, polyclonal antibody against the 84kD protein was prepared which recognizes the nuclear 60kD protein of HL-60. It was concluded that the 84kD protein of H. halobium has similar epitopes to the human c-myc protein. Our results are consistent with the observed homologies between a part of the genome of H. halobium and the v-myc oncogene (BenMahrez et al., 1988a) .
Using the archaebacterial 84kD protein ( Figure 5 ) or HL-60 extracts (Figures 6 & 7) as antigen, it was found that 21 out of 212 cancer patient sera contained circulating antibodies against the c-myc protein. The results obtained with either of the two antigens (84 and 60kD proteins) were the same. However, it is clear that the 84kD protein preparation has two advantages over HL-60 extracts viz. the simplicity of the response patterns and the relative ease of preparation of the 84kD protein.
Besides, it was shown by competition experiments that the positive sera reacted in a different manner with two peptides corresponding to two regions of the c-myc protein, probably indicating differences in the antibodies produced by the patients.
Although we have not studied a large panel of various cancer types statistically it appears that circulating antibodies to c-myc are not restricted to a particular type of cancer but are more likely to be present in patients with various types. The fact that many sera do not react with the 84 kD protein may be due to the absence of antibodies cross-reacting with the 84kD protein (independently of the fact that anti c-myc antibodies may be present) or to an inhibitory effect of idiotypic antibodies in these sera.
As the myc gene product is a nuclear protein (Persson & Leder, 1984b) , these antibodies could be classified among the antibodies to nuclear antigens (ANA), which have been clinically associated with numerous autoimmune diseases. In some malignant diseases ANAs may be important for diagnosis (Tan, 1982; Klein et al., 1974) . On the other hand, an immunization process may occur when the c-myc product is exposed to immunocompetent cells due to tumour lysis provoked by a therapeutically induced or natural tumour necrosis. This immunization could be more frequent when the tumour is infiltrated by mononuclear cells, or when the tumour is close to a lymphoid organ such as Peyer's patches in colon tumours (Martin et al., 1986) . Whether antibodies to the human c-myc protein reflect an autoimmune process or one induced by sensitisation during tumour necrotic or inflammatory processes remains to be studied.
